Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Interest Expenses (2020 - 2025)

Apellis Pharmaceuticals has reported Interest Expenses over the past 6 years, most recently at $10.8 million for Q4 2025.

  • Quarterly results put Interest Expenses at $10.8 million for Q4 2025, down 5.96% from a year ago — trailing twelve months through Dec 2025 was $44.3 million (up 9.74% YoY), and the annual figure for FY2025 was $44.3 million, up 9.74%.
  • Interest Expenses for Q4 2025 was $10.8 million at Apellis Pharmaceuticals, down from $11.3 million in the prior quarter.
  • Over the last five years, Interest Expenses for APLS hit a ceiling of $12.5 million in Q3 2024 and a floor of $1.2 million in Q4 2021.
  • Median Interest Expenses over the past 5 years was $7.8 million (2022), compared with a mean of $7.9 million.
  • Biggest five-year swings in Interest Expenses: crashed 87.51% in 2021 and later skyrocketed 544.83% in 2022.
  • Apellis Pharmaceuticals' Interest Expenses stood at $1.2 million in 2021, then skyrocketed by 544.83% to $7.7 million in 2022, then decreased by 4.34% to $7.4 million in 2023, then soared by 55.82% to $11.5 million in 2024, then decreased by 5.96% to $10.8 million in 2025.
  • The last three reported values for Interest Expenses were $10.8 million (Q4 2025), $11.3 million (Q3 2025), and $11.2 million (Q2 2025) per Business Quant data.